



# A Guide to Introducing a Second Dose of Measles Vaccine into Routine Immunization Schedules

**The Department of Immunization, Vaccines and Biologicals thanks the donors whose unspecified financial support has made the production of this document possible.**

This document was published by the Expanded Programme on Immunization of the Department of Immunization, Vaccines and Biologicals

Ordering code: WHO/IVB/13.03

Published in June 2013

**This publication is available on the Internet at:** [www.who.int/vaccines-documents/](http://www.who.int/vaccines-documents/)

**Copies of this document as well as additional materials on immunization, vaccines and biologicals may be requested from:**

World Health Organization  
Department of Immunization, Vaccines and Biologicals  
CH-1211 Geneva 27  
Switzerland  
Fax: + 41 22 791 4227  
Email: [vaccines@who.int](mailto:vaccines@who.int)

**© World Health Organization 2013**

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Art by Sophie Blackall, courtesy of the Measles and Rubella Initiative.

Design and layout by L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Printed by the WHO Document Production Services, Geneva, Switzerland.

# Content

Abbreviations .....	3
About this guide .....	4
Introduction .....	5
Decision-making at country level .....	7
What should be the process? .....	8
What information is needed? .....	8
What policies must be in place? .....	12
What opportunities are there to link with other programmes? .....	13
What impact (positive and negative) might MCV2 have on the national immunization schedule? .....	13
What can be learned from the introduction of new vaccines? .....	14
Planning .....	15
What is the best age to administer MCV2? .....	16
What is the estimated number of children targeted for MCV2? .....	16
What plans need to be made or revised? .....	17
How much will it cost to introduce MCV2? .....	18
How can MCV2 be integrated with other vaccinations and/or child health interventions? .....	19
Micro-planning for measles second dose vaccination .....	20
Vaccine management issues .....	21
How to forecast and calculate vaccine supply needed for MCV2? .....	21
What cold chain capacity will be required for MCV2? .....	22
Is it better to use a 10 or 5-dose vial of measles vaccine? .....	23
What impact does MCV2 introduction have on waste management? .....	23
Advocacy, communication and social mobilization .....	24
Communication regarding AEFI .....	28

<b>Implementation</b>	31
Training and supportive supervision	32
Service delivery	33
Demand creation	33
The opportunity and challenge of reaching toddlers	34
Providing service to children presenting later than the recommended age	35
School health and involvement of the education sector	35
<b>Monitoring and evaluation</b>	37
Immunization or child health card	38
Tally sheet	38
Immunization register	39
Defaulter tracking system	39
Integrated monthly report	41
Coverage/drop-out monitoring charts	42
Annual WHO/UNICEF Joint Reporting Form	42
EPI Programme Reviews	43
Vaccine safety monitoring (vaccine pharmacovigilance)	44
Post-introduction evaluation (PIE)	45
<b>Additional references</b>	47
<b>Annexes</b>	48

# Abbreviations

<b>AEFI</b>	adverse event following immunization
<b>BCC</b>	behaviour change communication
<b>cMYP</b>	comprehensive multi-year plans for immunization
<b>DTP</b>	diphtheria-tetanus-pertussis [vaccine]
<b>EPI</b>	Expanded Programme on Immunization
<b>IEC</b>	information, education and communication
<b>GAVI</b>	Global Alliance for Vaccines and Immunization
<b>JRF</b>	Joint Reporting Form
<b>LLIN</b>	Long-lasting insecticide treated bednet
<b>ICC</b>	Inter-Agency Coordinating Committee
<b>M</b>	measles [vaccine]
<b>MCV</b>	measles-containing vaccine
<b>MCV1</b>	first dose of MCV
<b>MCV2</b>	second dose of MCV
<b>MMR</b>	measles-mumps-rubella [vaccine]
<b>MR</b>	measles-rubella [vaccine]
<b>NITAG</b>	National Immunization Technical Advisory Group
<b>PCV</b>	pneumococcal conjugate vaccine
<b>RCV</b>	rubella-containing vaccine
<b>SAGE</b>	Strategic Advisory Group of Experts on immunization
<b>SIA</b>	supplementary immunization activity
<b>UNICEF</b>	United Nations Children's Fund
<b>WHO</b>	World Health Organization

# About this guide

This document is for national immunization programme managers and immunization partners involved in operational support.

Its objectives are:

- To guide the policy discussions and operational aspects of the introduction of a second dose of measles vaccine at a scheduled age into the routine immunization schedule.
- To provide up-to-date references on the global policy, the technical justification, and the strategic issues relating to the introduction and provision of a second dose of measles vaccine in the routine immunization programme.

# Introduction

The vision of “a world without measles” is supported by WHO, UNICEF and other partners in the newly released *Global Measles and Rubella Strategic Plan 2012–2020*<sup>1</sup>. The plan presents clear strategies that country immunization managers working with domestic and international partners can use as a blueprint to achieve the 2015 and 2020 measles control and elimination goals. The plan stresses the importance of strong routine immunization systems providing two doses of measles vaccine to each child, supplemented by campaigns, laboratory-backed surveillance, outbreak preparedness and case management, as well as research and development.

Strengthening routine immunization is critical as it is the foundation to achieving and sustaining high levels of population immunity to measles. For measles elimination, vaccination coverage needs to reach and remain at or exceed 95% with each of the two doses of MCV vaccines at the district and national levels. The challenge to achieve this will depend on enhanced implementation of the five components of the “Reaching Every District” (RED) approach to increase immunization coverage (see box below).

## Five “RED” components to increase immunization coverage

- ❶ **Planning and management of resources** – better management of human and financial resources.
- ❷ **Reaching target populations** – improving access to immunization services by all.
- ❸ **Linking services with communities** – partnering with communities to promote and deliver services.
- ❹ **Supportive supervision** – regular on-site teaching, feedback and follow-up with health staff.
- ❺ **Monitoring for action** – using tools and providing feedback for continuous self-assessment and improvement.

<sup>1</sup> Global Measles and Rubella Strategic Plan 2012–2020. WHO. 2012.



Since 2009<sup>2</sup> WHO has recommended that reaching all children with two doses of measles containing vaccine (MCV) should be the standard for all national immunization programmes.

When national coverage of MCV1  $\geq 80\%$ <sup>3</sup> has been achieved countries should consider introducing a second dose into their routine immunization schedule<sup>4</sup>. As routine coverage with two doses increases, campaigns will need to occur less frequently and can eventually cease altogether.

Taking the above mentioned policy and technical documents as its starting point, this guide “translates” the recommendations and evidence for introducing a routine second dose of measles vaccine into an easy to use “step-by-step” process.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28099](https://www.yunbaogao.cn/report/index/report?reportId=5_28099)

